Attar Eyal C.
Known title: Chief Medical OfficerCIK: 0001789076
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 6, 2026
Aprea Therapeutics Announces October Conference Presentations. Aprea Therapeutics will present at several conferences in October. The company’s appearance is intended to share progress on its research and development efforts. The presentation may offer new information to investors and analysts about the company’s pipeline and strategy. The event is a routine update for the company’s stakeholders.
Transaction History
| VOR | ▼ Sell | Open Market | 2,227 | $3K | 2/13/2025 | View on chart |
| VOR | ▼ Sell | Open Market | 2,554 | $3K | 2/10/2025 | View on chart |
| VOR | ▼ Sell | Tax Withholding | 1,180 | $2K | 2/6/2025 | View on chart |
| VOR | ▼ Sell | Tax Withholding | 1,353 | $2K | 2/3/2025 | View on chart |
| VOR | ▲ Buy | Grant | 52,500 | $0 | 2/3/2025 | View on chart |
| VOR | ▼ Sell | Open Market | 10,334 | $13K | 12/27/2024 | View on chart |
| VOR | ▼ Sell | Tax Withholding | 999 | $859 | 11/6/2024 | View on chart |
| VOR | ▼ Sell | Tax Withholding | 1,146 | $917 | 11/1/2024 | View on chart |
| VOR | ▼ Sell | Tax Withholding | 999 | $869 | 8/6/2024 | View on chart |
| VOR | ▼ Sell | Tax Withholding | 1,146 | $1K | 8/1/2024 | View on chart |
| VOR | ▼ Sell | Open Market | 14,645 | $20K | 6/3/2024 | View on chart |
| VOR | ▼ Sell | Tax Withholding | 999 | $2K | 5/6/2024 | View on chart |
| VOR | ▼ Sell | Tax Withholding | 1,146 | $2K | 5/1/2024 | View on chart |
| VOR | ▼ Sell | Tax Withholding | 1,180 | $3K | 2/6/2024 | View on chart |
| VOR | ▲ Buy | Grant | 62,500 | $0 | 1/29/2024 | View on chart |
| VOR | ▼ Sell | Tax Withholding | 999 | $2K | 11/6/2023 | View on chart |
| VOR | ▼ Sell | Tax Withholding | 999 | $3K | 8/7/2023 | View on chart |
| VOR | ▼ Sell | Tax Withholding | 969 | $4K | 5/8/2023 | View on chart |
| VOR | ▲ Buy | Grant | 54,500 | $0 | 2/6/2023 | View on chart |
| APRE | ▼ Sell | Tax Withholding | 32,667 | $26K | 6/3/2022 | View on chart |
| APRE | ▲ Buy | Grant | 42,900 | $0 | 3/10/2022 | View on chart |
| APRE | ▼ Sell | Open Market | 36,000 | $62K | 2/28/2022 | View on chart |
| APRE | ▼ Sell | Open Market | 15,968 | $75K | 9/16/2021 | View on chart |
| APRE | ▼ Sell | Tax Withholding | 9,032 | $36K | 8/25/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 15, 2026
Vor Biopharma Phase 3 data draws valuation focus
Recent analysis suggests Vor Biopharma may be undervalued as attention shifts to its Phase 3 data for generalized myasthenia gravis. This clinical milestone is central to the stock's current narrative, with analysts maintaining a wide range of price targets. The company's low trailing P/E ratio provides additional context for its current valuation relative to its 52-week trading range.
Vor Biopharma Phase 3 data draws valuation focus. Recent analysis suggests Vor Biopharma may be undervalued as attention shifts to its Phase 3 data for generalized myasthenia gravis. This clinical milestone is central to the stock's current narrative, with analysts maintaining a wide range of price targets. The company's low trailing P/E ratio provides additional context for its current valuation relative to its 52-week trading range.